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Expression of activated telomerase and subversion of the p16/pRb pathway is sufﬁcient and essential
for the in vitro immortalization of primary keratinocytes. Most cancers—including cervical
carcinoma—over-express hTERT, the catalytic domain of the telomerase complex.
Only a limited set of viruses within the Alphapapillomavirus genus are oncogenic. The viral functions
responsible for this distinction are not well understood. The human papillomavirus type 16 E6 protein
activates the hTERT promoter.
We used a luciferase-based assay to test the ability of 29 viral types, representing all current species
within the Alphapapillomavirus genus, to activate the hTERT promoter. We show that oncogenic types
speciﬁcally activate the hTERT promoter, while non-oncogenic types do not. Statistical analysis
supports the notion that activation of the hTERT promoter is uniquely associated with oncogenic
types, independent of evolutionary relationships. This ﬁnding begins to shed light on the viral
phenotypes correlated with oncogenic potential.
& 2012 Elsevier Inc. All rights reserved.The Papillomaviridae comprise a family of viruses that infect
most vertebrate species, while showing a high species speciﬁcity.
More than 150 HPV types have been described, and among them,
about 30–40 types infect the genital tract (Bernard et al., 2010; de
Villiers et al., 2004). Based on nucleotide similarity across the
major structural gene (L1), the PVs are divided into 29 genera, and
these genera are further divided into numbered species (Bernard
et al., 2010). Above the species level, the HPV types cluster into
three main genera, roughly corresponding to preferred tissue
tropism. The Alphapapillomavirus genus (alpha-PVs) contains all
the viral types that have been associated with anogenital cancer
in humans. Alpha-HPVs are categorized as ‘low-risk’ or ‘high-risk’
types, according to their epidemiological association with benign
or pre-cancerous and cancerous lesions, respectively (Bouvard
et al., 2009; IARC, 2012). Within the alpha-PV genus, the HR-clade
is monophyletic (Schiffman et al., 2005), suggesting that oncogen-
esis is an apomorphy (an acquired phenotype) associated with
this clade of the viral tree. Nevertheless, only a subset of types
within this HR-clade actually have oncogenic potential (oncogenicll rights reserved.
enter, Albert Einstein College
461, USA.
. Burk).
NIAID, NIH, 33 Northtypes, OTs) (Bouvard et al., 2009; IARC, 2012). It is, to date, not
known which of the viral phenotypes/activities are also asso-
ciated with oncogenesis. Traditionally, comparisons of HPV16 and
HPV6 have been used to address these questions (reviewed in
Klingelhutz and Roman, 2012). However, differences in viral
tropism and evolutionary history confound this paradigm
(Van Doorslaer and Burk, 2010).
In vitro assays have shown that disruption of the p16/pRb
pathway and induction of telomerase activity are sufﬁcient to
immortalize human epithelial cells (Garbe et al., 1999; Kiyono
et al., 1998; Lundberg et al., 2002). The E7 protein successfully
interacts with and degrades pRb and the other members of the
pocket family of proteins, thereby uncoupling the cells’ control of
E2F from normal mitogenic stimuli (Boyer et al., 1996; Helt and
Galloway, 2001). In addition, it has been demonstrated that
HPV16 E6 binds to the hTERT promoter and induces its expression
(Gewin and Galloway, 2001; Oh et al., 2001; Veldman et al., 2001;
Veldman et al., 2003) resulting in functional activation of the
telomerase complex. The proximal hTERT promoter contains two
E-boxes. These E-boxes are canonical binding sites for c-myc, a
strong activator of the hTERT promoter (Takakura et al., 1999). It
was shown that HPV16 E6 and c-myc cooperatively activate the
hTERT promoter in vivo (Veldman et al., 2003). The ubiquitin
ligase E6AP appears to play a key role in the activation of the
hTERT promoter (Gewin et al., 2004; James et al., 2006; Liu et al.,
2005). Moreover, it has been shown that induction of telomerase
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rather than p53 degradation is critical for immortalization of
epithelial cells by HPV16 (Kiyono et al., 1998; Klingelhutz et al.,
1996), although this view is not universally accepted (McMurray
and McCance, 2004). The consequence of perturbations in the
telomerase pathway during immortalization of primary kerati-
nocytes prompted us to analyze the importance of hTERT
activation in conjunction with available epidemiological and
evolutionary data. Using this approach, a viral phenotype/activ-
ity is correlated with carcinogenicity when only epidemiologi-
cally established oncogenic types exhibit the phenotype studied.
By analyzing the results of biochemical assays in this manner,
our lab has previously suggested that the degradation of p53 (Fu
et al., 2010) and PDZ containing proteins by the E6 protein was a
conserved phenotype of the high-risk clade; however, at least for
human alpha-PV infections, the degradation of these targets is
not strictly associated with cancer. In the present study we
analyzed the E6 proteins from 29 distinct viruses representing
the known evolutionary spectra of the alpha-PVs (Bernard et al.,0 1
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Fig. 1. hTERT promoter regulation by Alphapapillomavirus E6 proteins Left panel—phylo
this study were downloaded from GenBank and translated into amino-acid sequences.
Seaview (Gouy et al., 2010). HPV8 was used as the out-group to root the tree. The amin
the Seaview package (Gouy et al., 2010). The Bayesian tree shown in Fig. 1 was constru
the evolutionary model based on Modeltest (Posada and Crandall, 1998). Two chains of
Chain convergence was checked using AWTY (Nylander et al., 2008). Numbers at the nod
carcinogenicity was extrapolated from two recent reviews (Bouvard et al., 2009; IARC,
oncogenicity; white¼not oncogenic; X-ed¼potentially oncogenic; black¼ insufﬁcient
telomerase complex for the maintenance of telomere length (i.e. they use the ALT mech
hTERT promoter activity. While these cells were derived from a human osteosarcoma,
presented analysis. These U2OS were obtained from the ATCC and maintained in Dulbe
10% fetal bovine serum (Gemini bioproducts, West Sacramento, CA, USA). 100,000 U2
(Invitrogen, Carlsbad, CA, USA) according to the manufacturers’ instructions. 100 ng pQC
total of 800 ng including carrier DNA (pQCXIN empty vector). 24 h post transfection th
assayed using ﬁreﬂy luciferase (Dual luciferase Reporter assay system, Promega) on a BM
the BCA Protein assay kit (Thermo scientiﬁc, Waltham, MA, USA) and was used to norm
shown. The graph represents the mean signal of three independent experiments each pe
promoter was considered to be activated.2010; de Villiers et al., 2004). Epidemiological evidence was used
to classify viruses according to risk (Bouvard et al., 2009; IARC,
2012; Schiffman et al., 2009). hTERT promoter activation was
tested using a previously described luciferase based assay
(Veldman et al., 2001). In this assay, the hTERT minimal
promoter is cloned upstream of the luciferase reporter gene.
Activation of the promoter results in increased luciferase expres-
sion. To calibrate the assay, we measured the effects of c-myc
which is a strong activator of the hTERT promoter (reviewed in
Cerni, 2000). As shown in Fig. 1, c-myc activated the hTERT
promoter about 3.5-fold (compare top two rows). Based on the
activity of c-myc, we set the cut-off value for activation of the
hTERT promoter at three-fold activity over that driven by the
pQCXIN control vector (vertical dotted line on Fig. 1). To
demonstrate that the activation by c-myc was speciﬁc, we
used a construct in which both E-boxes (essential for c-myc
binding) were mutated (Veldman et al., 2001). When using this
construct no activation over background was observed (data
not shown).2 3 4 5 6 7 8 9
genetic tree- The nucleotide sequences for the E6 proteins of the types included in
The sequences were aligned using MAFFT (Katoh et al., 2002) as implemented in
o-acid sequence alignment was reverse-translated into a nucleotide alignment in
cted using MrBayes (Ronquist and Huelsenbeck, 2003). GTRþ IþG was selected as
10,000,000 generations were run and the ﬁrst 10,000 generations were discarded.
es indicate the viral species within the Alphapapillomavirus genus. Epidemiological
2012; Schiffman et al., 2009), and is indicated using colors. Gray branches indicate
evidence). U2OS cells express wild type p53 and pRb. These cells do not use the
anism). Preliminary analysis showed that these cells had low background levels of
it is unlikely that the choice of cell line signiﬁcantly inﬂuenced the results of the
cco’s modiﬁed Eagle’s medium (DMEM, Mediatech, Manassas, VA, USA) containing
OS cells were plated into 24-well plates and transfected using lipofectamine LTX
XIN based vector was mixed with 400 ng pGL3B-255wt (Veldman et al., 2001) in a
e cells were lysed in 100 ml Passive Lysis Buffer (Promega, Madison, WI, USA) and
G FLUOstar Optima plate reader. Total protein concentration was measured using
alize the luciferase signal. The fold changes over empty vector (¼background) are
rformed in triplicate (7SEM). The dotted line represents the level above which the
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tested for their ability to activate the hTERT promoter as mea-
sured by luciferase activity. The tested types represent all human
species groups (alpha 1–11, and 13–14; species 12 contains PVs
infecting non-human primates) in the Alphapapillomavirus genus,
with an over-representation of types within the HR-clade (alpha-
5, -6, -7 and -9). The Bayesian phylogenetic tree in Fig. 1 shows
the evolutionary relationships between all tested types. In addi-
tion, the coloring of the branches (oncogenic¼gray, Not onco-
genic¼white) indicates the epidemiological risk as classiﬁed by
the International Agency for Research on Cancer (Bouvard et al.,
2009; IARC, 2012). The ﬁgure shows that the majority of types
associated with cancer signiﬁcantly increased luciferase signals,
suggesting upregulated hTERT promoter activity. Since hTERT
levels are the limiting cellular factor for enzymatic activity, this
suggests activation of the hTERT complex. The only exception to
this pattern was the E6 from HPV56, which did not increase the
luciferase signal. Of note, none of the NOTs (e.g. HPV34, HPV70) in
the HR-clade augmented the hTERT promoter activity greater
than threefold above the control. HPV26 and HPV53 are not
considered oncogenic viruses, although they are embedded deep
within the HR-clade. While these viruses show a certain level of
upregulation of the hTERT promoter, this activation did not reach
the a-priori deﬁned cut-off. These results indicate a strong
correlation between hTERT promotor activation and cervix cancer
risk. To conﬁrm that hTERT activation did not just appear to be
correlated merely because it was inherited from a common
ancestor, we used a z-test to formally test whether hTERT
activation was associated with viral classiﬁcation based on
epidemiology (OT vs. NOT) or on phylogeny (HR vs. LR-clades).
94% (17/18) of viruses able to activate the hTERT promoter
belonged to the OT group, vs. 61% (11/18) belonging to the
HR-clade. The test had a z-value of 2.3708 with a p¼0.018. The
statistical analysis supports the notion that activation of the
hTERT promotor is associated with oncogenic classiﬁcation.
The clinical signiﬁcance of telomerase upregulation during
cervical carcinogenesis has been described in multiple studies
(Anderson et al., 1997; Branca et al., 2006; Frost et al., 2000;
Gorham et al., 1997; Iwasaka et al., 1998; Pao et al., 1997; Zhang
et al., 2002; Zhang et al., 1999). Telomerase activity parallels an
increase in the grade of cervical intraepithelial neoplasia, suggest-
ing an important role during the oncogenic process. Immuno-
histochemical staining showed that hTERT activity was signiﬁ-
cantly associated with the presence of HR-HPV DNA in the cell
(Branca et al., 2006) conﬁrming a link with viral gene expression.
In addition to these studies, the importance of hTERT activity has
been conﬁrmed in cell culture. Telomerase activity was shown to
be essential for the in vitro transformation of primary keratino-
cytes (Garbe et al., 1999; Kiyono et al., 1998; Lundberg et al.,
2002). It has been observed that while HPV positive cells have
induced telomerase activity, the telomeres of E6-transduced cells
do not increase in length during in vitro passaging (Stoppler et al.,
1997). Non-canonical functions independent of telomere-
lengthening by the telomerase enzyme might explain these
observations (Liu et al., 2009).
In the present study we show that in addition to alpha-species
9 (HPV16 and HPV16-related types), HPV18, HPV39 and HPV51
upregulate the hTERT promoter.
The types tested in this study are responsible for 95% of all
cervical cancers worldwide. The observation that all these types
upregulate telomerase activity supports the importance of hTERT
activation during HPV induced oncogenesis. HPV56 was the only
oncogenic type that was unable to transcriptionally regulate the
hTERT promoter in these experiments. However, the epidemiolo-
gical evidence supporting the oncogenicity of HPV56 is equivocal
(Schiffman et al., 2009).Since HPVs infect epithelial cells that undergo terminal differ-
entiation, all HPV types need to subvert the hosts’ control over the
cell cycle. Our previous work on p53 suggested that earlier steps
in the transformation process (e.g., apoptosis inhibition through
p53 degradation) are shared by all members of the HR-clade
irrespective of oncogenic risk (Fu et al., 2010). It is feasible that
the extended survival afforded through M2 crisis avoidance
initially provides the virus with an ideal environment for its
vegetative life cycle. However, the extended expression of both
oncogenes (i.e., E6 and E7) likely results in chromosomal instabil-
ity, and genetic and epigenetic changes in the host cell. This can
ultimately result in the malignant transformation of such persis-
tently infected cells. Since loss of cellular differentiation is not
compatible with a productive viral infection, it is likely that this
process represents ‘collateral damage’ of infection with a handful
of viruses that evolved this phenotype in order to complete their
lifecycle in a speciﬁc biological niche.
In conclusion, in the present study, we hypothesized that if
hTERT upregulation is a key function in cervical carcinogenesis,
oncogenic viral types should uniquely possess this activity. To test
this hypothesis, we assayed the effects of 29 E6 proteins isolated
from HPV types representing all species within the alpha-PV
genus. This approach allowed us to demonstrate that hTERT
promoter activity was associated with oncogenic risk, and dis-
cordant to evolutionary relationships.Acknowledgments
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